Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management

This study has been completed.
Sponsor:
Collaborator:
Merck S.A. de C.V., Mexico
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01364298
First received: May 31, 2011
Last updated: December 18, 2013
Last verified: December 2013

May 31, 2011
December 18, 2013
April 2011
July 2012   (final data collection date for primary outcome measure)
Change From Baseline in Average Numeric Pain Intensity Scale (NPIS) Score at Day 84 [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
An average NPIS pain score (daily average records of the past seven days) was evaluated. Numeric pain intensity scale (NPIS) is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. Change from baseline data has been calculated as value at baseline minus value at Day 84.
Average Numeric Pain Intensity Scale (NPIS) pain score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
An average NPIS pain score (daily average records of the past seven days). The patient express his/her experience of pain during the last 24 hours in NPIS that will be completed after wake up in the morning.
Complete list of historical versions of study NCT01364298 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Scale Score at Day 84 [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
    The LANSS scale score is 7-item pain scale that consists of grouped sensory description and sensory examination with simple scoring system. Evaluations in two main areas: pain and sensorial exploration. The first 5 questions asks for presence of unpleasant skin sensations (pricking, tingling, pins and needles), appearance of skin (mottled, red, or pink), increased sensitivity of skin to touch, sudden bursts of electric shock sensations, and hot or burning skin sensations. Last 2 questions involve sensory testing for the presence of allodynia and altered pinprick threshold. Different numbers of points, relative to their significance to neuropathic pain, are given to positive answers for maximum of 24 points. A score less than 12 makes unlikely that participant's symptoms are neuropathic in nature, whereas score more than 12 make neuropathic mechanisms likely to be contributing to participant's pain. Change from baseline data has been calculated as value at baseline minus value at Day 84.
  • Change From Baseline in Visual Analogue Scale (VAS) Score at Day 84 [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
    VAS is used to rate the pain as per 10 centimeter (cm) line. The pain intensity score ranges from '0=no pain' to '10=worst possible pain'. Change from baseline data has been calculated as value at baseline minus value at Day 84.
  • Profile of Mood States (POMS) Score [ Time Frame: Day 84 (Week 12) ] [ Designated as safety issue: No ]
    POMS is a rating scale, which comprises of 65 items that are evaluated in a 0-4 scale, where 0 means "not at all" and 4 "extremely". The scores for the 65 items are added in various combinations to throw six validated factors which are used to calculate total POMS score: (tension-anxiety) + (depression-dejection) + (anger-hostility)+ (fatigue-Inertia) + (confusion-bewilderment) - (vigor-activity). Score range (-40 to 192). Score -40 denotes the best score and score 192 denotes the worst score.
  • Sleep Evaluation: Number of Participants Who Fell Asleep in Pre-specified Time Duration [ Time Frame: Day 84 (Week 12) ] [ Designated as safety issue: No ]
    Sleep evaluation was performed by assessing number of participants who fell asleep in a particular pre-specified range of time duration, that is, 0-15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and greater than 60 minutes at Day 84 (Week 12).
  • Number of Participants With Various Health Conditions Based on Global Impression of Patient Change (GIPC) Scale [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
    GIPC is an assessment that the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse).
  • Number of Participants With Various Health Conditions Based on Clinical Global Impression of Change (CGIC) Scale [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
    CGIC is an assessment that the physician performs to assess the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse).
  • Percentage of Participants With at Least 30 and 50 Percent (%) Improvement in Numeric Pain Intensity Scale (NPIS) From Baseline at Day 84 (Week 12) [ Time Frame: Baseline and Day 84 (Week 12) ] [ Designated as safety issue: No ]
    NPIS is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours.
  • Number of Participants With Adverse Events (AEs) [ Time Frame: Day 7 up to Day 84 (+7 days) ] [ Designated as safety issue: Yes ]
    An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered.
  • Leeds assessment of neuropathic symptoms and signs (LANSS) scale [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Short-Form McGill Pain Questionnaire Visual Analogue Scale (SF-MPQ VAS) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    The intensity increases from "0=no pain" to "10=worst possible pain"
  • Profile of Mood States (POMS) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Sleep evaluation [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    It will be measured how long the patient lasts to get to sleep during one week averagely.
  • Patient's Global Impression of Change (PGIC) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    PGIC is a subject global change assessment made by the patient experienced since start of the study in a 7-point scale where "1 = best" and "7 = worst"
  • Clinical Global Impression of Change (CGIC) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Assessment that physician makes about global change experienced by the subject since the study onset, using the same 7-point scale described in the preceding paragraph for PGIC and obtained at the end of the study.
  • Proportion of responders (patients with at least a 30% and 50% average pain score decrease from baseline to the end of the study) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Number of Patients with Adverse Events (AEs) [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management
Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain

This is a multicenter, randomized, open-label, parallel, Phase 4 clinical trial to compare efficacy and safety of gabapentin/B-complex versus pregabalin in diabetic peripheral neuropathy pain (DPNP) management.

Primary Objective:

To compare the efficacy of gabapentin/B-complex versus pregabalin administered for 12 weeks in the treatment of pain in mild to moderate diabetic peripheral neuropathy (DPN) of acute or chronic presentation.

Secondary Objectives:

To determine the safety and tolerability of gabapentin/B-complex versus pregabalin administered for 12 weeks in the treatment of pain in mild to moderate DPN of acute or chronic presentation.

Subjects will be randomized in a 1:1 ratio to receive gabapentin/B-complex or pregabalin.

The duration of treatment per subject will be 12 weeks.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetic Peripheral Neuropathic Pain
  • Drug: Gabapentin/B-complex
    Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
    Other Name: Gavindo®
  • Drug: Pregabalin
    Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
    Other Name: Lyrica®
  • Experimental: Gabapentin/B-complex
    Intervention: Drug: Gabapentin/B-complex
  • Active Comparator: Pregabalin
    Intervention: Drug: Pregabalin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
353
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Females or males undististincally
  • Age 18 to 70 years
  • Signed informed consent (IC) by the subject
  • Diabetes mellitus (DM) Type 1 or 2
  • Pain due to sensorial or motor DPN of low to moderate intensity, greater than or equal to (>=) 1 year of evolution and less than or equal to (=<)5 years of being diagnosed
  • Subjects who score >=40 millimeter (mm) in the visual analogue scale (VAS) of the McGill pain questionnaire (MPQ) at selection and Baseline visit, and who complete on a daily basis the numeric pain intensity (NPI) (at least 4 days a week) during the week previous to randomization and whose daily mean score is of at least 4, during the 7 days previous to randomization (with a wash-out period)
  • Normal chest radiography
  • Stable hypoglycemic treatment, at least 6 weeks before randomization
  • Glycosylated hemoglobin (HbA1c) =<10 percent at selection visit
  • Women must not be pregnant and must not have pregnancy plans during the period of the study duration
  • Subjects not medicated or under analgesic stable medication during a minimum of 4 weeks, where no acceptable relief of pain is achieved; in the last case, with the corresponding wash-out period
  • Women of childbearing age must submit a negative pregnancy test before treatment randomization and should use a contraceptive method medically accepted, during the study period

Exclusion Criteria:

  • Suicide risk defined as a score of 2 or higher, in question 9 of the beck depression test
  • Congestive heart failure Class III or IV of the New York Heart Association (NYHA)
  • Subjects with serious or unstable coronary heart disease, hepatic, kidney, respiratory, hematological alterations, problems with peripheral vascular disease, or other medical or psychiatric conditions that can put in risk the participation of the subject in the study or that may lead to hospitalization during the study period
  • Any condition that may lead to confusion of the diagnostic of painful DPN, in particular amputations -other than fingers/toes-, not diabetic neurological disorder and skin conditions that may affect sensation at the painful limbs
  • Subjects with Baseline calculated creatinine clearance less than (<) 60 milliliter per minute (mL/min), Baseline leukocyte count < 2,500 per cubic millimeter (/mm^3), Baseline neutrophils count < 1,500/mm^3 or platelets < 100 * 10^3 /mm^3
  • Subjects who have participated previously in some other study of pregabalin or gabapentin or gabapentin/B-complex, during 30 days previous to selection
  • Subjects with encephalopathy caused by ammonia with alterations in the cycle of urea
  • Subjects with uncontrolled closed-angle glaucoma
  • Subject with presence of a disorder or an anticonvulsant treatment
  • Breastfeeding women or during the first 3 months postpartum
  • Morbid obesity (body mass index [BMI] >=40)
  • Glycosylated hemoglobin (HbA1c) greater than (>) 10 percent
  • Major surgery 3 months previous to randomization
  • Any surgery 2 weeks previous to randomization process, or programmed during the study period should have been authorized by the Sponsor or appointed representative
  • Blood donors 60 days previous to randomization
  • Abuse or dependency of alcohol, narcotics, opioids or any other addictive substances, or energizing drinks
  • History of hypersensitivity to the drugs in the study or drugs with similar chemical structures
  • History or suspicion of lack of trust, poor cooperation of lack of compliance of medical treatments
  • Subjects with arthritis, sciatic, fibromyalgia, restless leg syndrome, non-neuropathic muscle-skeletal pain or back chronic pain
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT01364298
EMR200054-603 CL028
Yes
Merck KGaA
Merck KGaA
Merck S.A. de C.V., Mexico
Study Director: Clinical Research Manager Merck S.A de C.V, Mexiko, an affiliate of Merck KGaA, Darmstadt, Germany
Merck KGaA
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP